Table 2.

Comparison of the diagnostic value of FR+CTC with tumor biomarkers

Biomarkers	AUC	95% CI	P-value	Cutoff threshold	Sensitivity	Specificity
Lung cancer (n=23) versus noncancer (n=40)
FR+CTC	0.7810	0.6605–0.9015	0.0002	10.0	95.7%	65.0%
CA125	0.7716	0.6439–0.8992	0.0005	29.9	77.3%	74.4%
CA199	0.5425	0.3821–0.7029	0.5836	17.9	54.6%	64.1%
CEA	0.6247	0.4626–0.7868	0.1081	7.3	45.5%	89.7%
CYFRA21-1	0.7770	0.6566–0.8975	0.0003	4.8	78.3%	71.8%
CA724	0.6280	0.4345–0.8214	0.1635	6.0	42.9%	91.7%
NSE	0.7770	0.6537–0.9003	0.0003	13.4	56.5%	87.2%
Colorectal cancer (n=8) vs noncancer (n=40)
FR+CTC	0.7641	0.5596–0.9685	0.0195	17.0	62.5%	85.0%
CA125	0.5160	0.2775–0.7545	0.8875	56.4	37.5%	84.6%
CA199	0.7179	0.5194–0.9165	0.0543	18.3	75.0%	64.1%
CEA	0.5593	0.3306–0.7880	0.6005	3.2	87.5%	38.5%
CYFRA21-1	0.5369	0.3160–0.7577	0.7448	4.0	75.0%	43.6%
CA724	0.6007	0.3556–0.8458	0.3776	5.8	37.5%	91.7%
NSE	0.6907	0.5155–0.8659	0.0922	9.5	100%	38.5%
All cancers (n=34) vs noncancer (n=40)
FR+CTC	0.7507	0.6367–0.8647	0.0002	10.0	85.7%	65.0%
CA125	0.7036	0.5812–0.8260	0.0028	29.9	64.7%	74.4%
CA199	0.6037	0.4708–0.7366	0.1284	17.9	58.8%	64.1%
CEA	0.6044	0.4698–0.7391	0.1257	6.3	41.2%	87.2%
CYFRA21-1	0.6753	0.5501–0.8006	0.0102	4.8	61.8%	71.8%
CA724	0.5978	0.4439–0.7517	0.2024	5.8	37.5%	91.7%
NSE	0.7711	0.6639–0.8783	<0.0001	13.2	58.8%	87.2%

Notes: CYFRA21-1, CA724, and NSE tests had not performed for the lymphoma patient; thus, this patient was excluded from this analysis.

Abbreviation: AUC, area uner the curve; CI, confidence interval; FR+CTC, folate receptor-positive circulating tumor cell; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin 19 fragment antigen; NSE, neuron-specific enolase.